about
Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer.HLA class I and II expression in oropharyngeal squamous cell carcinoma in relation to tumor HPV status and clinical outcomePrevalence of human papillomavirus and survival in oropharyngeal cancer other than tonsil or base of tongue cancer.Incidence of IP and risk of malignant transformation in the Swedish population 1960-2010.Cancer of the gingiva.Differential survival trends for patients with tonsillar, base of tongue and tongue cancer in Sweden.Incidence of human papillomavirus positive tonsillar and base of tongue carcinoma: a stabilisation of an epidemic of viral induced carcinoma?Human papillomavirus prevalence in mouthwashes of patients undergoing tonsillectomy shows dominance of HPV69, without the corresponding finding in the tonsils.A model for predicting clinical outcome in patients with human papillomavirus-positive tonsillar and base of tongue cancer.Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7.Management of the neck in node-positive tonsillar cancer.Early deterioration in Bell's palsy: prognosis and effect of prednisolone.Prediction of nonrecovery in Bell's palsy using Sunnybrook grading.Presence of human papillomaviruses and p16 expression in hypopharyngeal cancer.Validation of a Swedish version of the Facial Disability Index (FDI) and the Facial Clinimetric Evaluation (FaCE) scale.Human papillomavirus and survival in patients with base of tongue cancer.The human carotid body releases acetylcholine, ATP and cytokines during hypoxia.Sinonasal malignancies in Sweden 1960-2010; a nationwide study of the Swedish population.Survival in patients with human papillomavirus positive tonsillar cancer in relation to treatment.The role of human papillomavirus in the increased incidence of base of tongue cancer.The incidence of tonsillar cancer in Sweden is increasingQuantification of Trapezius Muscle Innervation During Neck DissectionsA descriptive study highlighting the differences in the treatment protocol for oral tongue cancer in Sweden and Finland
P50
Q34567933-4C010B7C-3B8F-4A6F-8915-9F6D5CD716E9Q35018702-F530E77C-E468-4A79-AD96-DC0AC84C1019Q36530626-B7F316EC-EEF8-4FCB-86D7-1404EC130C05Q37642140-4C3EEDF3-3B87-4FA8-B8F8-FCF5C99FC0A7Q38343302-9270B411-104F-4C31-B0FE-9630D1D94324Q38438639-35158062-8788-45D9-B6A1-CDE95D0914B1Q40240768-CAD029C6-C760-4060-B6B9-8F3CA3C7293DQ40292220-D6AAAFFB-F946-4C06-9CF3-9FF4A25513C7Q40888230-C89D69A3-0DA6-4849-B7CF-A45E3F6800A6Q41251899-B02A6DE5-EB15-4ECA-BBA6-298B35300F00Q41739742-9D4F9BB3-9637-42F2-8F41-76881CA1FC3AQ42917276-9FCF8F49-5CC5-4751-A9DD-50CCDA03BD66Q44754219-3ECCB383-A4B6-412B-8ADE-F9E126200DB7Q44817366-994F7426-0399-46CA-9B23-209296B82561Q45239942-FBAC2B32-17BE-42BD-9ADE-E05DC3302B4CQ46762989-67524B77-B0A5-44E8-B7DF-D2392AE167BAQ53045648-FBE078F4-9603-40A6-9DA0-D2921E939E06Q53588854-5FD1CE19-BE7E-415B-B9EA-D3314DB646ACQ54341743-00D58181-B5A6-4EFF-B421-41BB9429384EQ54457505-06013046-959F-44D5-8D8D-E26333BE40B5Q58083891-3C4F3015-6AF0-473B-92AA-D7F562BAC0B0Q61860408-28EF4B9F-19F0-4DB2-BFAC-CED11DFC34D7Q92090376-A7208187-33AA-4E29-8BB7-E9726BFC7C5C
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Lalle Hammarstedt-Nordenvall
@ast
Lalle Hammarstedt-Nordenvall
@en
Lalle Hammarstedt-Nordenvall
@es
Lalle Hammarstedt-Nordenvall
@sl
type
label
Lalle Hammarstedt-Nordenvall
@ast
Lalle Hammarstedt-Nordenvall
@en
Lalle Hammarstedt-Nordenvall
@es
Lalle Hammarstedt-Nordenvall
@sl
prefLabel
Lalle Hammarstedt-Nordenvall
@ast
Lalle Hammarstedt-Nordenvall
@en
Lalle Hammarstedt-Nordenvall
@es
Lalle Hammarstedt-Nordenvall
@sl
P106
P21
P31
P496
0000-0003-1660-9737